4.7 Article

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Related references

Note: Only part of the references are listed.
Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

Article Medicine, Research & Experimental

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

Shirin Kalimuddin et al.

Summary: The study showed that spike-specific T cells and binding antibodies were detectable 10 days after the first dose of the Pfizer/Bio-NTech BNT162b2 vaccine, suggesting that early T cell and binding antibody responses may induce early protection against COVID-19 compared to receptor blocking or virus neutralizing activity.
Article Biochemistry & Molecular Biology

A serological assay to detect SARS-CoV-2 seroconversion in humans

Fatima Amanat et al.

NATURE MEDICINE (2020)

Letter Medicine, General & Internal

Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York

Rebecca Haberman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)